PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.26%
Negative revenue growth while CSIQ stands at 30.81%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
22.85%
Gross profit growth under 50% of CSIQ's 130.09%. Michael Burry would be concerned about a severe competitive disadvantage.
64.97%
Positive EBIT growth while CSIQ is negative. John Neff might see a substantial edge in operational management.
64.97%
Operating income growth under 50% of CSIQ's 908.68%. Michael Burry would be concerned about deeper cost or sales issues.
-42.17%
Negative net income growth while CSIQ stands at 1047.95%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-48.00%
Negative EPS growth while CSIQ is at 1000.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-42.80%
Negative diluted EPS growth while CSIQ is at 1000.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-2.93%
Share reduction while CSIQ is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.67%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
250.43%
OCF growth of 250.43% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
86.11%
FCF growth of 86.11% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
3606.18%
10Y revenue/share CAGR at 50-75% of CSIQ's 5160.35%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
3606.18%
5Y revenue/share CAGR at 50-75% of CSIQ's 5160.35%. Martin Whitman would worry about a lagging mid-term growth trajectory.
3606.18%
3Y revenue/share CAGR at 50-75% of CSIQ's 5160.35%. Martin Whitman would question if the firm lags behind competitor innovations.
1285.43%
OCF/share CAGR of 1285.43% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
1285.43%
OCF/share CAGR of 1285.43% while CSIQ is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
1285.43%
3Y OCF/share CAGR of 1285.43% while CSIQ is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
145.49%
Below 50% of CSIQ's 1544.27%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
145.49%
Below 50% of CSIQ's 1544.27%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
145.49%
Below 50% of CSIQ's 1544.27%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.42%
AR growth is negative/stable vs. CSIQ's 24.39%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
40.59%
Inventory growth well above CSIQ's 7.59%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
7.61%
Asset growth well under 50% of CSIQ's 34.41%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
5.78%
50-75% of CSIQ's 9.03%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-149.74%
Our R&D shrinks while CSIQ invests at 11.79%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
15.74%
SG&A growth well above CSIQ's 30.50%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.